ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-...
Entos Pharmaceuticals Inc (Entos), a clinical-stage company that develops genetic medicines utilizing its non-viral, redosable Fusogenix PLV delive...
CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processi...
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory mul...
Charles River Laboratories International, Inc. has announced the successful completion of its acquisition of PathoQuest, a specialist in ne...
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targ...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new ...
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...
MasterControl, a leading provider of quality and manufacturing software solutions for life sciences and regulated industries, has a...
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...
Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoi...
Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces that its new state-of –the-art ...
© 2026 Biopharma Boardroom. All Rights Reserved.
